{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:37:21Z","timestamp":1789519041318,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005041","name":"Universit\u00e9 Catholique de Louvain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016338","name":"Imperial Experimental Cancer Medicine Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116821","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:18:12Z","timestamp":1779466692000},"page":"116821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1\/2 trial in patients with advanced solid tumours"],"prefix":"10.1016","volume":"242","author":[{"given":"Robert H.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":false,"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-5466","authenticated-orcid":false,"given":"James","family":"Korolewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8491-2178","authenticated-orcid":false,"given":"Karam","family":"Aboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cienne","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Cosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Benafif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3274-9427","authenticated-orcid":false,"given":"Stephanie R.","family":"Edmondson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9981-421X","authenticated-orcid":false,"given":"Jeremy R.A.","family":"Paull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3756-4495","authenticated-orcid":false,"given":"Nicola J.","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116821_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116821_bib2","unstructured":"U.S. Food and Drug Administration: FDA approves lower dose of cabazitaxel for prostate cancer, 2017 \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lower-dose-cabazitaxel-prostate-cancer\u3009 [accessed 13 January 2026]."},{"key":"10.1016\/j.ejca.2026.116821_bib3","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m(2)) and the currently approved dose (25 mg\/m(2)) in post-docetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116821_bib4","unstructured":"Sandoz Inc. Jevtana (cabazitaxel) injection prescribing information, 2023 \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208715s000lbl.pdf\u3009 [accessed 13 January 2026]."},{"key":"10.1016\/j.ejca.2026.116821_bib5","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.21873\/anticanres.14529","article-title":"Cabazitaxel - a treatment option in recurrent platinum-resistant ovarian cancer","volume":"40","author":"Madsen","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2026.116821_bib6","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1158\/1078-0432.CCR-19-3920","article-title":"Multicenter phase II study of Cabazitaxel in advanced gastroesophageal cancer: association of HER2 expression and M2-like tumor-associated macrophages with patient outcome","volume":"26","author":"Shah","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116821_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00432-017-2565-5","article-title":"CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach","volume":"144","author":"Schmalenberg","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116821_bib8","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-1716","article-title":"Abstract 1716: anticancer activity of the taxane nanoparticles, DEP\u00ae docetaxel and DEP\u00ae cabazitaxel","volume":"80","author":"Kelly","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116821_bib9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.drudis.2006.07.005","article-title":"Exploiting the enhanced permeability and retention effect for tumor targeting","volume":"11","author":"Iyer","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ejca.2026.116821_bib10","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2217\/nnm.11.67","article-title":"Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties","volume":"6","author":"Kaminskas","year":"2011","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.ejca.2026.116821_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","article-title":"Design and optimisation of dendrimer-conjugated Bcl-2\/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy","volume":"4","author":"Patterson","year":"2021","journal-title":"Commun Biol"},{"issue":"26","key":"10.1016\/j.ejca.2026.116821_bib12","first-page":"2918","article-title":"Dendrimer-nanoparticle (DEP) delivery of topoisomerase I inhibitor, SN38 (DEP-SN38): safety, tolerability, and preliminary efficacy study in patients with advanced solid tumors","volume":"43","author":"Liu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116821_bib13","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116821_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116821_bib15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116821_bib16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejca.2014.01.006","article-title":"Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme","volume":"50","author":"Heidenreich","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116821_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2012.07.008","article-title":"Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study","volume":"49","author":"Di\u00e9ras","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116821_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-014-2638-y","article-title":"A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA)","volume":"75","author":"Kang","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2026.116821_bib19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2026.116821_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1312","article-title":"Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy","volume":"9","author":"Molassiotis","year":"2019","journal-title":"Brain Behav"},{"issue":"1","key":"10.1016\/j.ejca.2026.116821_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11764-021-00988-x","article-title":"Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review","volume":"17","author":"Timmins","year":"2023","journal-title":"J Cancer Surviv"},{"issue":"611","key":"10.1016\/j.ejca.2026.116821_bib22","article-title":"An emerging aspect of cancer neuroscience: a literature review on chemotherapy-induced peripheral neuropathy","volume":"28","author":"Tao","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejca.2026.116821_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdh007","article-title":"Phase II study of irinotecan and 5-fluorouracil\/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma","volume":"15","author":"Assersohn","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116821_bib24","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/annonc\/mdm004","article-title":"Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer","volume":"18","author":"Ilson","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116821_bib25","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116821_bib26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/oncolo\/oyad096","article-title":"Paclitaxel with or without cixutumumab as second-line treatment of metastatic esophageal or gastroesophageal junction cancer: a randomized phase II ECOG-ACRIN trial","volume":"28","author":"Stockton","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.116821_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.23.01771","article-title":"Treatment approaches for platinum-resistant ovarian cancer","volume":"42","author":"St Laurent","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:55:30Z","timestamp":1781153730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"alternative-id":["S0959804926006027"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116821","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1\/2 trial in patients with advanced solid tumours","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116821"}}